Omeros (OMER) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.85
- Estimate
- -$0.02
- Surprise
- -4142.0%
- Revenue (period 2026-09-30)
- $35.9M
- Score today
- 4.5/10
Revenue source: xbrl.
How the report landed
Omeros (OMER) reported a wider loss than forecast — adjusted EPS of -$0.85 against the -$0.02 estimate (a 4142.0% shortfall).
Coverage in the report window
- Omeros Corporation Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-16
- 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga, 2026-11-16
- Omeros Q3 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $35.934M Miss $37.267M Estimate — benzinga, 2026-11-16
Where TrendMatrix's rating stands now
TrendMatrix currently rates OMER Sell at 4.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -4142.0% surprise compares with a -956.0% four-quarter average.
What argues against it
- Concentration risk — Product: YARTEMLEA
- Concentration risk — Supplier: Lonza
- Cyclical trap - fwd PE 70x vs trail 14x (5.1x)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.68
- Price target
- $23.38
- Stop
- $15.63
- Upside to target
- +40.2%
- Reward-to-risk
- 3.6:1
Forward estimates sit below the trailing run-rate (69.5× forward vs 13.7× trailing) — consensus expects earnings to decline from here.
Risk check: trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
OMER at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.21B
- P/E (fwd)
- 69.5
- P/E (ttm)
- 13.7
- 52-week range
- $6.70–$21.24
- Off 52-week high
- 21.5%
- RSI (14)
- 45
- Volume vs avg
- 1.58×
- Score today
- 4.5/10